Endologix Inc. (ELGX)

5.65
NASDAQ : Health Technology
Prev Close 5.44
Day Low/High 5.32 / 5.74
52 Wk Low/High 3.75 / 6.50
Avg Volume 503.30K
Exchange NASDAQ
Shares Outstanding 84.01M
Market Cap 457.01M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Endovascular Aneurysm Sealing (EVAS) With Nellix System Associated With Higher Survival Than Traditional Endovascular Aneurysm Repair (EVAR) In New Study

Endovascular Aneurysm Sealing (EVAS) With Nellix System Associated With Higher Survival Than Traditional Endovascular Aneurysm Repair (EVAR) In New Study

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the results of a study, which was presented by Marc Schermerhorn, M.

Endologix, Inc. To Announce First Quarter 2018 Financial Results On May 2, 2018

Endologix, Inc. To Announce First Quarter 2018 Financial Results On May 2, 2018

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2018 after the market...

Endologix Reports Positive Results From Global ENCORE Analysis With Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation Abdominal Stent Graft Systems

Endologix Reports Positive Results From Global ENCORE Analysis With Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation Abdominal Stent Graft Systems

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the first results from ENCORE, a pooled, global analysis of several prospective clinical trials and...

Endologix, Inc. Announces Enrollment Of The First Patient In EVAS2 IDE Clinical Study Of The Nellix® EndoVascular Aneurysm Sealing System

Endologix, Inc. Announces Enrollment Of The First Patient In EVAS2 IDE Clinical Study Of The Nellix® EndoVascular Aneurysm Sealing System

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was treated in the EVAS2 IDE Confirmatory Clinical Study of the...

John McDermott Steps Down As Chief Executive Officer Of Endologix, Inc.

John McDermott Steps Down As Chief Executive Officer Of Endologix, Inc.

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott is stepping down as the Company's Chief Executive Officer.

Endologix Reports Fourth Quarter And Fiscal Year 2017 Financial Results

Endologix Reports Fourth Quarter And Fiscal Year 2017 Financial Results

Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2017.

Endologix, Inc. Completes Patient Enrollment In The ELEVATE IDE Clinical Study

Endologix, Inc. Completes Patient Enrollment In The ELEVATE IDE Clinical Study

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today the completion of enrollment in the E xpanding Patient Applicability with Po l ymer S e aling...

Endologix, Inc. To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Endologix, Inc. To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present...

Endologix Appoints Greg Morrow As Chief Marketing Officer And Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix Appoints Greg Morrow As Chief Marketing Officer And Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Greg Morrow as the Company's Chief Marketing Officer, effective immediately.

Endologix, Inc. To Announce Fourth Quarter And Fiscal Year 2017 Financial Results On February 21, 2018

Endologix, Inc. To Announce Fourth Quarter And Fiscal Year 2017 Financial Results On February 21, 2018

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the fourth quarter and fiscal year 2017 after the market...

Endologix Becomes Oversold (ELGX)

Endologix Becomes Oversold (ELGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Endologix, Inc. To Present At The J.P. Morgan Healthcare Conference

Endologix, Inc. To Present At The J.P. Morgan Healthcare Conference

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present...

Endologix Reaches Analyst Target Price

Endologix Reaches Analyst Target Price

In recent trading, shares of Endologix Inc. have crossed above the average analyst 12-month target price of $5.33, changing hands for $5.39/share.

Endologix, Inc. To Present At The Piper Jaffray 29th Annual Healthcare Conference

Endologix, Inc. To Present At The Piper Jaffray 29th Annual Healthcare Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, will present at the Piper Jaffray 29 th Annual Healthcare...

Endologix Reports Third Quarter 2017 Financial Results

Endologix Reports Third Quarter 2017 Financial Results

Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the third quarter ended September 30, 2017.

ELGX Crosses Above Average Analyst Target

ELGX Crosses Above Average Analyst Target

In recent trading, shares of Endologix Inc. have crossed above the average analyst 12-month target price of $5.70, changing hands for $5.92/share.

Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq:ELGX) ("Endologix"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to its newly appointed Chief Operating...

Endologix, Inc. To Present At The Stifel 2017 Healthcare Conference

Endologix, Inc. To Present At The Stifel 2017 Healthcare Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present...

Endologix Appoints John Onopchenko As Chief Operating Officer

Endologix Appoints John Onopchenko As Chief Operating Officer

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed John Onopchenko as the Company's Chief Operating Officer, effective October...

Short Interest In Endologix Drops 12.2%

Short Interest In Endologix Drops 12.2%

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 1,880,477 share decrease in total short interest for Endologix Inc. , to 13,525,718, a decrease of 12.21% since 09/15/2017.

Endologix, Inc. To Announce Third Quarter 2017 Financial Results On November 7, 2017

Endologix, Inc. To Announce Third Quarter 2017 Financial Results On November 7, 2017

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the third quarter of fiscal year 2017 after the market...

Endologix Receives IDE Approval For The EVAS2 Confirmatory Clinical Study To Evaluate The Nellix® EndoVascular Aneurysm Sealing System

Endologix Receives IDE Approval For The EVAS2 Confirmatory Clinical Study To Evaluate The Nellix® EndoVascular Aneurysm Sealing System

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") approval from the United States...

Endologix Announces CE Mark Approval For The Nellix® EndoVascular Aneurysm Sealing System With The Refined Indications For Use

Endologix Announces CE Mark Approval For The Nellix® EndoVascular Aneurysm Sealing System With The Refined Indications For Use

Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the CE Mark approval for its Nellix ® EndoVascular Aneurysm Sealing System ("Nellix") with the...

Endologix Announces Collaboration Agreements With Japan Lifeline For The Development And Commercialization Of Thoracic Endovascular Systems In Japan

Endologix Announces Collaboration Agreements With Japan Lifeline For The Development And Commercialization Of Thoracic Endovascular Systems In Japan

Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has signed a joint research and development agreement, as well as an exclusive distribution...

Endologix Announces Positive Clinical Results From The LEOPARD Clinical Study

Endologix Announces Positive Clinical Results From The LEOPARD Clinical Study

Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced positive interim results from the LEOPARD ( Looking at  Evar  Outcomes...

TheStreet Quant Rating: D (Sell)